drugset
drugset / Trial / NCT05462340

PET Imaging Study of α7 and α4β2-nAChR in Schizophrenia

NCT05462340 ↗

Phase 1 Terminated 117 enrolled Washington University School of Medicine
Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

The purpose of this research is to use specialized brain imaging techniques, Positron Emission Tomography (PET) scan and Magnetic Resonance Imaging (MRI), to learn more about the brain chemistry, e.g., how neurotransmitters and receptors in the brain function in people with schizophrenia compared to healthy controls.

Timeline

Start
2022-08-18
Primary completion
2025-01-07
Completion
2025-01-07

Outcome

Outcome not reported

Stopped (Enrollment): “Study recruitment milestones were not met.”

Drugs

EvaluationDrugModalityDoseRoute
Subject [18F]ASEM Diagnostic / imaging agent — —
Subject [18F]AZAN Unknown — —

Indications

schizophrenia